The Obinutuzumab Biosimilar CD20 Antibody is a cutting-edge biopharmaceutical product specifically designed to target the CD20 protein, a key marker on B cells, in the treatment of various autoimmune disorders and cancers. This biosimilar antibody, inspired by the successful drug Obinutuzumab, offers a cost-effective and reliable alternative for researchers and clinicians looking to study and utilize CD20 therapy.With high affinity and specificity towards CD20, this antibody is ideal for use in laboratory research, preclinical studies, and clinical trials aiming to understand and harness the therapeutic potential of targeting CD20-positive cells.
By effectively binding to CD20, this biosimilar antibody can elicit potent immune responses against cancer cells or autoimmune targets, making it a versatile tool for drug development and personalized medicine.Whether investigating the role of CD20 in lymphomas, leukemias, rheumatoid arthritis, or multiple sclerosis, the Obinutuzumab Biosimilar Anti-CD20 Antibody offers researchers a reliable and consistent reagent to advance our knowledge of B cell biology and immune modulation. Its proven efficacy and affordability make it a valuable asset for the scientific community striving to improve patient care and outcomes in the field of immunotherapy.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
GA101, RG7159, RO5072759, afutuzumab
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
